Cargando…

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease

Maintaining consistent levodopa benefits while simultaneously controlling dyskinesia can be difficult. Recently, an amantadine delayed release/extended release (DR/ER) formulation (Gocovri(®)) indicated for dyskinesia received additional FDA approval as an adjunct to levodopa for the treatment of OF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hauser, Robert A., Lytle, Judy, Formella, Andrea E., Tanner, Caroline M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933492/ https://www.ncbi.nlm.nih.gov/pubmed/35304480 http://dx.doi.org/10.1038/s41531-022-00291-1

Ejemplares similares

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2021)

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
por: Mehta, Shyamal H., et al.
Publicado: (2021)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)
por: Oertel, Wolfgang, et al.
Publicado: (2017)

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
por: Hauser, Robert A., et al.
Publicado: (2017)

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
por: Elmer, Lawrence W., et al.
Publicado: (2018)

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2020)

Amantadine ER (Gocovri(®)) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
por: Hauser, Robert A., et al.
Publicado: (2021)

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018)

Potential utility of amantadine DR/ER in persons with Parkinson’s disease meeting 5-2-1 criteria for device aided therapy
por: Hauser, Robert A., et al.
Publicado: (2021)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets
por: deVries, Tina, et al.
Publicado: (2019)

Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease
por: Muhlack, Siegfried, et al.
Publicado: (2010)

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Carbamazepine extended-release capsules in bipolar disorder
por: Weisler, Richard H
Publicado: (2006)

A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment
por: Cohen, Jeffrey A, et al.
Publicado: (2021)

Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2020)

Amantadine, COVID-19 and Parkinsonism
por: Wiwanitkit, Viroj
Publicado: (2020)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Response to: Amantadine, COVID-19 and Parkinsonism
por: Aranda-Abreu, Gonzalo Emiliano
Publicado: (2020)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Erroneous formulation of delayed-release omeprazole capsules: alert for importing countries
por: Rahman, Mohammad Sofiqur, et al.
Publicado: (2017)

Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019)

Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011)

Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease
por: Mao, Zhongping Lily, et al.
Publicado: (2016)

Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary(®)): Results of a Nationwide Dose Conversion Survey
por: Hauser, Robert A., et al.
Publicado: (2021)

A developed composite hard-gelatin capsules: delayed-release enteric properties
por: Nezhad Mohseni, Mozhgan, et al.
Publicado: (2022)

Amantadine Ameliorates Dopamine-Releasing Deficits and Behavioral Deficits in Rats after Fluid Percussion Injury
por: Huang, Eagle Yi-Kung, et al.
Publicado: (2014)

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Amantadine-Induced Patulous Eustachian Tubes in Parkinson's Disease
por: Boyd, J. T., et al.
Publicado: (2013)

The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules
por: Pavloff, Nadine, et al.
Publicado: (2018)

Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
por: Langman, Craig B.
Publicado: (2023)

Serotonin-releasing agents with reduced off-target effects
por: Mayer, Felix P., et al.
Publicado: (2022)

Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
por: deVries, Tina, et al.
Publicado: (2019)

Development and validation of dissolution testings in acidic media for rabeprazole sodium delayed-release capsules
por: Tan, Yinhe, et al.
Publicado: (2016)

Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
por: Hauser, Robert A., et al.
Publicado: (2014)

Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release
por: Benedek, Irma H, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qjcvd1ce6anf6jv2sn3pecbatp